Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

This study has been completed.

Sponsored by:	Hvidovre University Hospital
Information provided by:	Hvidovre University Hospital
ClinicalTrials.gov Identifier:	NCT00115947

Purpose

The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function.

Hypothesis: Significant improvement of renal function reflected by: glomerular filtration rate (GFR), renal blood flow (RBF), excretion of salt and metabolites in the urine and related hormones and peptides in the blood. No effect on the systolic function of the heart.

Condition	Intervention	Phase
Cirrhosis Ascites	Drug: Terlipressin	Phase II Phase III

MedlinePlus related topics: Cirrhosis

Drug Information available for: Terlipressin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study

Further study details as provided by Hvidovre University Hospital:

Study Start Date:	December 2004
Estimated Study Completion Date:	January 2006

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Cirrhosis and ascites

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00115947

Locations

Denmark, Hvidovre
Hvidovre Hospital
Copenhagen, Hvidovre, Denmark, 2650

Sponsors and Collaborators

Hvidovre University Hospital

Investigators

Principal Investigator:

Aleksander Krag Krag, MD

Hvidovre Hospital

More Information

Study ID Numbers:	2004-000568-29
Study First Received:	June 26, 2005
Last Updated:	March 8, 2006
ClinicalTrials.gov Identifier:	NCT00115947
Health Authority:	Denmark: Danish Medicines Agency

Study placed in the following topic categories:

Liver Diseases
Digestive System Diseases
Fibrosis

Ascites
Terlipressin
Liver Cirrhosis

Additional relevant MeSH terms:

Pathologic Processes
Therapeutic Uses
Vasoconstrictor Agents

Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009